| Diabetes Mellitus, Non-Insulin-Dependent
Jentadueto vs Lyumjev
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Jentadueto vs Lyumjev with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLyumjev has a higher rate of injection site reactions vs Jentadueto based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lyumjev but not Jentadueto, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jentadueto
Lyumjev
At A Glance
Oral
Twice daily
DPP-4 inhibitor / biguanide
SC injection
With each meal
Rapid-acting insulin analog
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Individualized dosing orally twice daily with meals; starting at 2.5 mg linagliptin/500 mg metformin HCl twice daily for metformin-naive patients, maximum 2.5 mg linagliptin/1,000 mg metformin HCl twice daily; contraindicated if eGFR <30 mL/min/1.73 m2; initiation not recommended if eGFR 30-45 mL/min/1.73 m2.
Diabetes Mellitus, Non-Insulin-Dependent Administer U-100 or U-200 SC at meal start or within 20 minutes after starting a meal into abdomen, upper arm, thigh, or buttocks; U-100 also available via CSII insulin pump or IV infusion (under medical supervision, diluted to 1 unit/mL); individualize dose based on metabolic needs and glucose monitoring.
Contraindications
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to linagliptin, metformin, or any excipient in JENTADUETO
- Episodes of hypoglycemia
- Hypersensitivity to insulin lispro-aabc or any excipient in LYUMJEV
Adverse Reactions
Most common (>=5%) Nasopharyngitis, diarrhea (combination); diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache (metformin initiation)
Serious Lactic acidosis, pancreatitis, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, vitamin B12 deficiency, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, rash, cholestatic/hepatocellular/mixed liver injury
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, infusion site reaction, infusion site pain
Serious Hypoglycemia (including severe), severe hypersensitivity reactions (anaphylaxis, angioedema, bronchospasm, hypotension, shock)
Postmarketing Localized cutaneous amyloidosis at injection site, hyperglycemia or hypoglycemia associated with injection into areas of localized cutaneous amyloidosis
Pharmacology
Linagliptin is a DPP-4 inhibitor that increases active incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin release and reducing glucagon secretion; metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Rapid-acting human insulin analog that binds insulin receptors to stimulate peripheral glucose uptake in skeletal muscle and fat and inhibit hepatic glucose production, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jentadueto
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (11/12)
Lyumjev
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (8/12)
UnitedHealthcare
Jentadueto
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Lyumjev
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Jentadueto
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Lyumjev
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Jentadueto.
No savings programs available for Lyumjev.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JentaduetoView full Jentadueto profile
LyumjevView full Lyumjev profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.